, E! ~+ j, W$ |: W0 G5 h' g临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究: 1 L. m, i6 d/ B/ O$ ~Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.* o% W% r4 ~* z. M/ r9 F http://www.ncbi.nlm.nih.gov/pubmed/22968184/ B* l* x0 L% r) C- V